Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 53

1.

PlGF/VEGFR-1 Signaling Promotes Macrophage Polarization and Accelerated Tumor Progression in Obesity.

Incio J, Tam J, Rahbari NN, Suboj P, McManus DT, Chin SM, Vardam TD, Batista A, Babykutty S, Jung K, Khachatryan A, Hato T, Ligibel JA, Krop IE, Puchner SB, Schlett CL, Hoffmman U, Ancukiewicz M, Shibuya M, Carmeliet P, Soares R, Duda DG, Jain RK, Fukumura D.

Clin Cancer Res. 2016 Jun 15;22(12):2993-3004. doi: 10.1158/1078-0432.CCR-15-1839. Epub 2016 Feb 9.

PMID:
26861455
2.

Vascular endothelial growth factor A: just one of multiple mechanisms for sex-specific vascular development within the testis?

Sargent KM, McFee RM, Spuri Gomes R, Cupp AS.

J Endocrinol. 2015 Nov;227(2):R31-50. doi: 10.1530/JOE-15-0342. Epub 2015 Oct 15. Review.

3.

The cellular response to vascular endothelial growth factors requires co-ordinated signal transduction, trafficking and proteolysis.

Smith GA, Fearnley GW, Tomlinson DC, Harrison MA, Ponnambalam S.

Biosci Rep. 2015 Aug 18;35(5). pii: e00253. doi: 10.1042/BSR20150171. Review.

4.

Powerful anti-tumor and anti-angiogenic activity of a new anti-vascular endothelial growth factor receptor 1 peptide in colorectal cancer models.

Cicatiello V, Apicella I, Tudisco L, Tarallo V, Formisano L, Sandomenico A, Kim Y, Bastos-Carvalho A, Orlandi A, Ambati J, Ruvo M, Bianco R, De Falco S.

Oncotarget. 2015 Apr 30;6(12):10563-76.

5.

Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer.

Allen JW, Moon J, Redman M, Gadgeel SM, Kelly K, Mack PC, Saba HM, Mohamed MK, Jahanzeb M, Gandara DR.

J Clin Oncol. 2014 Aug 10;32(23):2463-70. doi: 10.1200/JCO.2013.51.4109. Epub 2014 Jul 7.

6.

FLT1 genetic variation predisposes to neovascular AMD in ethnically diverse populations and alters systemic FLT1 expression.

Owen LA, Morrison MA, Ahn J, Woo SJ, Sato H, Robinson R, Morgan DJ, Zacharaki F, Simeonova M, Uehara H, Chakravarthy U, Hogg RE, Ambati BK, Kotoula M, Baehr W, Haider NB, Silvestri G, Miller JW, Tsironi EE, Farrer LA, Kim IK, Park KH, DeAngelis MM.

Invest Ophthalmol Vis Sci. 2014 May 8;55(6):3543-54. doi: 10.1167/iovs.14-14047.

7.

Quantitative fluorescent profiling of VEGFRs reveals tumor cell and endothelial cell heterogeneity in breast cancer xenografts.

Imoukhuede PI, Popel AS.

Cancer Med. 2014 Apr;3(2):225-44. doi: 10.1002/cam4.188. Epub 2014 Jan 22.

8.

Ziv-aflibercept in metastatic colorectal cancer.

Patel A, Sun W.

Biologics. 2014;8:13-25. doi: 10.2147/BTT.S39360. Epub 2013 Dec 16. Review.

9.

The dynamics of developmental and tumor angiogenesis-a comparison.

Jin Y, Jakobsson L.

Cancers (Basel). 2012 Apr 11;4(2):400-19. doi: 10.3390/cancers4020400.

10.

PET with 62Cu-ATSM and 62Cu-PTSM is a useful imaging tool for hypoxia and perfusion in pulmonary lesions.

Zhang T, Das SK, Fels DR, Hansen KS, Wong TZ, Dewhirst MW, Vlahovic G.

AJR Am J Roentgenol. 2013 Nov;201(5):W698-706. doi: 10.2214/AJR.12.9698.

11.

AUF1-RGG peptides up-regulate the VEGF antagonist, soluble VEGF receptor-1 (sFlt-1).

Fellows A, Mierke DF, Nichols RC.

Cytokine. 2013 Oct;64(1):337-42. doi: 10.1016/j.cyto.2013.05.019. Epub 2013 Jun 14.

12.

Peptides modeled on the RGG domain of AUF1/hnRNP-D regulate 3' UTR-dependent gene expression.

Fellows A, Deng B, Mierke DF, Robey RB, Nichols RC.

Int Immunopharmacol. 2013 Sep;17(1):132-41. doi: 10.1016/j.intimp.2013.05.014. Epub 2013 Jun 5.

13.

Vascular-targeted therapies for Duchenne muscular dystrophy.

Ennen JP, Verma M, Asakura A.

Skelet Muscle. 2013 Apr 23;3(1):9. doi: 10.1186/2044-5040-3-9.

14.

Brain homeostasis: VEGF receptor 1 and 2-two unequal brothers in mind.

Wittko-Schneider IM, Schneider FT, Plate KH.

Cell Mol Life Sci. 2013 May;70(10):1705-25. doi: 10.1007/s00018-013-1279-3. Epub 2013 Mar 12. Review.

15.

Both Kdr and Flt1 play a vital role in hypoxia-induced Src-PLD1-PKCĪ³-cPLA(2) activation and retinal neovascularization.

Singh NK, Hansen DE 3rd, Kundumani-Sridharan V, Rao GN.

Blood. 2013 Mar 7;121(10):1911-23. doi: 10.1182/blood-2012-03-419234. Epub 2013 Jan 14.

16.

Antiangiogenesis therapy in the treatment of metastatic colorectal cancer.

Grothey A, Allegra C.

Ther Adv Med Oncol. 2012 Nov;4(6):301-19. doi: 10.1177/1758834012454464.

17.

Expression of VEGF receptors on endothelial cells in mouse skeletal muscle.

Imoukhuede PI, Popel AS.

PLoS One. 2012;7(9):e44791. doi: 10.1371/journal.pone.0044791. Epub 2012 Sep 12.

18.

PlGF: a multitasking cytokine with disease-restricted activity.

Dewerchin M, Carmeliet P.

Cold Spring Harb Perspect Med. 2012 Aug 1;2(8). pii: a011056. doi: 10.1101/cshperspect.a011056. Review.

19.

Signal transduction by vascular endothelial growth factor receptors.

Koch S, Claesson-Welsh L.

Cold Spring Harb Perspect Med. 2012 Jul;2(7):a006502. doi: 10.1101/cshperspect.a006502. Review.

20.

Elevated vascular endothelial growth factor receptor-2 abundance contributes to increased angiogenesis in vascular endothelial growth factor receptor-1-deficient mice.

Ho VC, Duan LJ, Cronin C, Liang BT, Fong GH.

Circulation. 2012 Aug 7;126(6):741-52. doi: 10.1161/CIRCULATIONAHA.112.091603. Epub 2012 Jun 29.

Items per page

Supplemental Content

Write to the Help Desk